Pith. sign in

REVIEW

ARANet: Attention-based Residual Adversarial Network with Deep Supervision for Radiotherapy Dose Prediction of Cervical Cancer

Not yet reviewed by Pith; the record is open.

This paper has not been read by Pith yet. Machine review is queued; the pith claim, tier, and objections will appear here once it completes.

SPECIMEN: schema-true, not a live event

T0 review · schema-true

One-sentence machine reading of the paper's core claim.

pith:XXXXXXXX · record.json · timestamp

arxiv 2408.13981 v1 pith:UYW4KKGE submitted 2024-08-26 cs.CV

ARANet: Attention-based Residual Adversarial Network with Deep Supervision for Radiotherapy Dose Prediction of Cervical Cancer

classification cs.CV
keywords dosecancercervicalnetworkaranetdeeppredictionresidual
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved
0 comments
read the original abstract

Radiation therapy is the mainstay treatment for cervical cancer, and its ultimate goal is to ensure the planning target volume (PTV) reaches the prescribed dose while reducing dose deposition of organs-at-risk (OARs) as much as possible. To achieve these clinical requirements, the medical physicist needs to manually tweak the radiotherapy plan repeatedly in a trial-anderror manner until finding the optimal one in the clinic. However, such trial-and-error processes are quite time-consuming, and the quality of plans highly depends on the experience of the medical physicist. In this paper, we propose an end-to-end Attentionbased Residual Adversarial Network with deep supervision, namely ARANet, to automatically predict the 3D dose distribution of cervical cancer. Specifically, given the computer tomography (CT) images and their corresponding segmentation masks of PTV and OARs, ARANet employs a prediction network to generate the dose maps. We also utilize a multi-scale residual attention module and deep supervision mechanism to enforce the prediction network to extract more valuable dose features while suppressing irrelevant information. Our proposed method is validated on an in-house dataset including 54 cervical cancer patients, and experimental results have demonstrated its obvious superiority compared to other state-of-the-art methods.

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.